Actually Obleix is right n = 10 is quite low (although fine for rare diseases). Even though it says statistically significant we will need to get way more data on who the patients where (m/f, age, progression of disease, amt of ARB, blood-drug levels etc.) before we can break out the champagne. Secondly, only seven of those qualified for final analysis.
It does help to say that with a small study, we will need more info as investors/doctors/patients/mgmt before we are confident of us shareholders getting some big pay days. De-risking this will include some form of licensing deal I would imagine.
That is why a Ph3 is needed next with a much larger pop. Else on just the Ph2 we could go straight to commercialization.
As a holder I am happy for the company and everyone involved. As an investor, I await more info and a ph3.
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-59
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M |
Open | High | Low | Value | Volume |
46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 21052 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.490 |
1 | 38000 | 0.485 |
2 | 19350 | 0.480 |
2 | 114893 | 0.470 |
2 | 14280 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 21052 | 1 |
0.500 | 106103 | 3 |
0.505 | 100000 | 1 |
0.510 | 129000 | 3 |
0.515 | 160650 | 4 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |